Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity.
about
DNA methylation and microRNA dysregulation in cancerEffective DNA/RNA co-extraction for analysis of microRNAs, mRNAs, and genomic DNA from formalin-fixed paraffin-embedded specimensMicroRNA expression as risk biomarker of breast cancer metastasis: a pilot retrospective case-cohort study.Prognostic significance of microRNA-375 downregulation in solid tumors: a meta-analysis.Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management.Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas.Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens.The role of microRNAs in breast cancer migration, invasion and metastasismicroRNA Expression in Prospectively Collected Blood as a Potential Biomarker of Breast Cancer Risk in the BCFR.Hsa-miR-375 is a predictor of local control in early stage breast cancer.Prediction of miRNA-disease associations with a vector space modelComprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma.MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib.MicroRNA-224 inhibits proliferation and migration of breast cancer cells by down-regulating Fizzled 5 expression.PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.MicroRNA-224 suppresses colorectal cancer cell migration by targeting Cdc42.The functional significance of microRNA-375 in human squamous cell carcinoma: aberrant expression and effects on cancer pathways.The emerging role of miR-375 in cancer.Functional significance of aberrantly expressed microRNAs in prostate cancer.Non-coding RNAs in Mammary Gland Development and Disease.MicroRNA 375 regulates proliferation and migration of colon cancer cells by suppressing the CTGF-EGFR signaling pathway.E2F1 induces miR-224/452 expression to drive EMT through TXNIP downregulationTumour-suppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer.Biological networks in Parkinson's disease: an insight into the epigenetic mechanisms associated with this diseasePrediction of miRNA-disease Associations using an Evolutionary Tuned Latent Semantic Analysis.Aberrant miRNA promoter methylation and EMT-involving miRNAs in breast cancer metastasis: Diagnosis and therapeutic implications.MicroRNA expression in benign breast tissue and risk of subsequent invasive breast cancer.Low expression of miRNA-224 predicts poor clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP.MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1.MicroRNA and Breast Cancer: Understanding Pathogenesis, Improving Management.miRmapper: A Tool for Interpretation of miRNA⁻mRNA Interaction Networks
P2860
Q26998741-EB649969-3557-4268-B9B3-10BF4E9AB39EQ28482346-D35455E8-7AF8-4133-80C0-D3DDC151AA9AQ30591772-D5EF7752-AC2A-4575-956F-9395FE3F1E68Q34488086-2CE6AA68-192F-4F66-A7FA-F4252A4F6AA6Q35094742-6BDB54DB-1163-4B92-8FDB-62B3C24325EEQ35952029-48B460E1-2BD0-42E0-9608-111DA9E0F495Q36320751-86D10796-8CAC-4234-BECF-78C44DAA97C3Q36396579-4447473B-6BF7-4801-BA3D-E55614A6004CQ36647044-BA8A7E6C-1BB0-4432-9E14-D4E557861047Q36668028-C8C37761-B6E1-4F64-8C26-188F3A654621Q36953740-83A4D874-3B33-4D1F-B7B8-31B9459FF960Q37293498-B2BC83D5-6B33-49AE-8A15-0607775DF574Q37327513-D425974C-C5CD-4E82-A53C-47402A210B8DQ37580183-9D6EF5B1-16AF-4C24-ABBD-B9392E668FF5Q37589094-81391188-1971-470B-A946-661356D1A2EEQ37731426-F948628D-704F-4BF6-A0DC-3EE6F9354C22Q38020381-83E99F25-2C3A-4305-8028-754A26FDE8EEQ38156047-1B20E98A-C2D0-4358-AB05-1C64FDF333B7Q38323461-DC8A6FC5-60E4-42C1-8463-917F3B3AF78EQ38667231-9EB9B322-DB62-4EB4-BB63-8B87AE3FCC4FQ38697327-A0D36865-8412-43B8-893E-98C40AAC9BF1Q38945520-83BB9C2B-01CE-41E8-B363-E9FD5AED0D4EQ39001066-E96D39D0-E8EB-4529-A4EF-5C3F671DE654Q41150803-27560AB2-7F96-406E-8DA2-77D75C4CF9E4Q41621167-1492B4B6-2175-4650-B2A0-DA5890B6723AQ48297890-21B35651-B3C2-4D99-91EA-6650737CDFFFQ50062445-D2B8DE36-F36C-4B2B-A298-C257833A70C0Q53368987-1B3CD4F8-F12E-4529-879E-056555896F95Q54387126-7D494F6F-8CC7-446E-B5EF-D252D80A1994Q54944098-4569F09E-B3F6-4C81-B064-23390F4FFFD9Q58739072-B7644BEA-4087-40D1-B4D6-7A2D0DD0EFEF
P2860
Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Hsa-miR-375 is differentially ...... ss of mammary acinar polarity.
@en
type
label
Hsa-miR-375 is differentially ...... ss of mammary acinar polarity.
@en
prefLabel
Hsa-miR-375 is differentially ...... ss of mammary acinar polarity.
@en
P2093
P2860
P356
P1476
Hsa-miR-375 is differentially ...... oss of mammary acinar polarity
@en
P2093
Andrew Ramnauth
Christina Liu
Geoffrey Childs
Lesley Stead
Nella Shapiro
Olivier Loudig
Orsi Giricz
Paraic A Kenny
Susan Fineberg
P2860
P304
P356
10.1002/PATH.2978
P577
2011-09-26T00:00:00Z